Skip to main content
Equibles

4967 · KOBAYASHI PHARMACEUTICAL CO.,LTD. · Financials

Use 4967 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4967.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
7,003 JPY +2 (+0.03%) At close · Nov 10
Rebalance outlook locked
Market Cap
520.59B JPY
Shares
74.34M
Volume · Nov 10 211.9K Avg daily vol (3M) 263.61K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
165.74B +0.1%
FY2025 Revenue FY2021–FY2025
Net Income
3.66B -63.7%
FY2025 Net Income FY2021–FY2025
Gross Margin
51.11% -1.8pp
FY2025 Gross Margin FY2021–FY2025
Operating Margin
9% -6pp
FY2025 Operating Margin FY2021–FY2025
Operating Cash Flow
25.59B +127.5%
FY2025 Operating Cash Flow FY2021–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2025 FY2024 FY2023 FY2022 FY2021
JPY 165.74B 165.6B 173.46B 166.26B 155.25B
JPY 81.03B 78B 77.08B 73.93B 66.48B
JPY 84.71B 87.6B 96.38B 92.33B 88.77B
JPY 14.92B 24.86B 25.78B 26.67B 26.07B
JPY 3.74B 13.91B 27.56B 27.95B 27.64B
JPY 83M 3.84B 7.22B 7.93B 7.92B
JPY 3.66B 10.07B 20.34B 20.02B 19.72B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: 35.14B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.